Delayed Onset of Linezolid-induced Peripheral Neuropathy: A Case Report and Review with Symptom of Atypical Timeframes
Abstract
Linezolid, a key drug in Multidrug-resistant Tuberculosis (MDR-TB) treatment, is known for its efficacy but is frequently associated with peripheral neuropathy, particularly with prolonged use. The authors hereby present a case of a 17-year-old young female diagnosed with extra-pulmonary MDR-TB, who developed delayed-onset peripheral neuropathy after five months of Linezolid therapy. She initially tolerated an all-oral longer regimen, including Bedaquiline, Linezolid, Cycloserine, Clofazimine, Levofloxacin and Pyridoxine. However, she later reported tingling and numbness in both lower limbs, with hyperesthesia. A neurological examination confirmed sensory axonal neuropathy. Linezolid was discontinued, leading to symptomatic improvement. To confirm, a rechallenge was performed, starting with 300 mg once daily and increasing to 600 mg once daily. Within a week, symptoms recurred, reinforcing the diagnosis of Linezolid-induced Peripheral Neuropathy (LIPN). The drug was permanently discontinued and replaced with Pyrazinamide as per Programmatic Management of Drug-resistant Tuberculosis (PMDT) guidelines. Despite its importance in MDR-TB management, there is a lack of standardised protocols for monitoring and mitigating LIPN. Future research should focus on dose-response relationships, adjunctive therapies and biochemical markers such as folate, homocysteine and oxidative stress indicators to refine treatment strategies. A balanced approach is crucial to ensuring efficacy while…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.